Trial Profile
Phase II Multicenter Single Arm Study to Evaluate the Efficacy and Safety of Ibrutinib in Combination to Rituximab-CHOP Followed by Ibrutinib Maintenance in Untreated Patients With Activated-B-Cell (ABC)-DLBCL at Intermediate-high and High Risk (IPI ≥2)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Jan 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Therapeutic Use
- 27 Dec 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Dec 2023.
- 27 Dec 2022 Planned End Date changed from 1 Feb 2025 to 1 Jul 2027.
- 27 Dec 2022 Planned primary completion date changed from 1 Feb 2023 to 1 Jul 2023.